These NLRP3 data may show a link between intestinal inflammation and CRC, and may pave the way for a new therapy strategy that targets the NLRP3-MAPK-mTOR-S6K1 axis to improve the prognosis of CRC patients [110]. Here, MTOR is linked to colorectal carcinoma.